Edition:
India

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

113.35EUR
19 Jan 2018
Change (% chg)

€1.90 (+1.70%)
Prev Close
€111.45
Open
€111.60
Day's High
€114.20
Day's Low
€111.00
Volume
86,159
Avg. Vol
107,000
52-wk High
€129.85
52-wk Low
€71.01

Chart for

About

Ipsen SA is a France-based pharmaceutical company. The Company is focused on various therapeutic areas, including onocology, endocrinology, neurosciences and primary care. Its onocology portfolio includes Somatuline, Decapeptyl, Hexvix and Cabometyx. Its endocrinology portfolio includes Increlex and NutropinAq. Its primary care... (more)

Overall

Beta: 0.75
Market Cap(Mil.): €9,633.51
Shares Outstanding(Mil.): 83.66
Dividend: 0.85
Yield (%): 0.74

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients

* EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

17 Jan 2018

BRIEF-Ipsen Appoints Richard Paulson Executive VP And CEO Of Ipsen North America

* IPSEN APPOINTS RICHARD PAULSON EXECUTIVE VICE-PRESIDENT AND CHIEF EXECUTIVE OFFICER OF IPSEN NORTH AMERICA Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

12 Jan 2018

BRIEF-Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​

* ‍ANNOUNCED RESULTS FROM PHASE III STUDY DEMONSTRATING EFFICACY AND SAFETY OF DYSPORT(ABOBOTULINUMTOXINA) IN ADULT PATIENTS ​

29 Nov 2017

BRIEF-Ipsen ‍reports Q3 2017 group sales growth of 22.6%​

* Q3 GROUP SALES EUR ‍​470.1 MILLION VERSUS EUR 390.6 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

26 Oct 2017

BRIEF-Ipsen announces success of phase 3 CELESTIAL trial of Cabozantinib

* IPSEN ANNOUNCES THAT PHASE 3 CELESTIAL TRIAL OF CABOZANTINIB MEETS PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

16 Oct 2017

BRIEF-Ipsen receives approval from European Commission for Xermelo

* Ipsen receives approval from European Commission for Xermelo® (Telotristat Ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

19 Sep 2017

BRIEF-FDA approves new indication for Ipsen's somatuline depot injection

* U.S. FDA approves new indication for Ipsen's somatuline® depot (lanreotide) injection for the treatment of carcinoid syndrome Source text for Eikon: Further company coverage:

18 Sep 2017

BRIEF-Ipsen annouces US FDA approval of new indication for Somatuline Depot

* U.S. FDA APPROVES NEW INDICATION FOR IPSEN'S SOMATULINE DEPOT (LANREOTIDE) INJECTION FOR THE TREATMENT OF CARCINOID SYNDROME Source text for Eikon: Further company coverage: (Gdynia Newsroom)

18 Sep 2017

BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial

* ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

11 Sep 2017

Pharma group Ipsen raises margin target after strong H1

July 27 French pharmaceutical group Ipsen raised its annual margin target on Thursday on the back of a strong first half, boosted by its core speciality care business which includes oncology and endocrinology products.

27 Jul 2017

Earnings vs. Estimates